29.11.2012 Views

Pharmaceutical Administration and Regulations in Japan - Nihs

Pharmaceutical Administration and Regulations in Japan - Nihs

Pharmaceutical Administration and Regulations in Japan - Nihs

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

manufacturer submits an MF registration<br />

application, it is necessary to appo<strong>in</strong>t a drug<br />

substance manager to h<strong>and</strong>le the activities of<br />

the MF registrant <strong>in</strong> <strong>Japan</strong>.<br />

When the registered contents of the MF<br />

are changed, an application to change the<br />

MF or a slight MF modification notification<br />

must be submitted. However, new<br />

registration applications are required <strong>in</strong> cases<br />

where there is concern that the change <strong>in</strong><br />

registered items will alter the basic nature of<br />

registered items.<br />

When an application to change of the MF<br />

is submitted, the market<strong>in</strong>g authorization<br />

holder must submit a partial change<br />

application or a slight modification notification<br />

for the MF depend<strong>in</strong>g on the contents of the<br />

change. However, when a change or<br />

changes are slight, the market<strong>in</strong>g<br />

authorization holder is not required to submit<br />

a partial change application or a slight<br />

modification notification of approved items.<br />

In both cases, MF registrants must notify the<br />

market<strong>in</strong>g authorization holder or the<br />

manufactur<strong>in</strong>g approval holder of the<br />

change(s).<br />

When approval applications are filed us<strong>in</strong>g<br />

MF registration, a copy of the registration<br />

certificate <strong>and</strong> a copy of the contract with the<br />

registrant related to MF utilization are<br />

required. When <strong>in</strong>quiries concern<strong>in</strong>g MF<br />

registration arise <strong>in</strong> the course of the review,<br />

<strong>in</strong>quiries directly from the PMDA are made to<br />

<strong>Pharmaceutical</strong> <strong>Regulations</strong> <strong>in</strong> <strong>Japan</strong>:<br />

the registrant or the drug substance<br />

manager. When changes are made <strong>in</strong> the<br />

registered contents as a result of the review,<br />

the MF registrant must submit an application<br />

for a change <strong>in</strong> registered content or a slight<br />

modification notification without delay.<br />

3.7 Accreditation of Overseas<br />

Manufacturers<br />

Persons wish<strong>in</strong>g to manufacture drugs,<br />

quasi-drugs, cosmetics, or medical devices<br />

exported to <strong>Japan</strong> from overseas (overseas<br />

manufacturers) must receive accreditation<br />

from the M<strong>in</strong>ister (enforced from April 1,<br />

2005).<br />

The specifications for accreditation are the<br />

same as those for manufactur<strong>in</strong>g licenses for<br />

domestic manufacturers.<br />

The follow<strong>in</strong>g items are taken from the<br />

“Q&A on Accreditation of Overseas<br />

Manufacturers” <strong>in</strong> an office communication of<br />

the Evaluation <strong>and</strong> Licens<strong>in</strong>g Division, PFSB<br />

dated February 14, 2006. Refer to the<br />

PMDA homepage for reference.<br />

http://www.pmda.go.jp/operations/shon<strong>in</strong>/i<br />

nfo/foreign.html (<strong>in</strong> <strong>Japan</strong>ese)<br />

(1) Applicants for accreditation of<br />

overseas manufacturers <strong>and</strong> their<br />

agents<br />

- When the applicant is a corporation,<br />

the representative (director with<br />

representative authority) makes the<br />

2011-3 - 26 -

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!